Literature DB >> 31486036

Design and Production of Newcastle Disease Virus for Intratumoral Immunomodulation.

Gayathri Vijayakumar1,2, Dmitriy Zamarin3,4,5.   

Abstract

Newcastle disease virus (NDV) is an avian paramyxovirus that has been extensively studied as an oncolytic agent, in addition to being an economically important pathogen in the poultry industry. The establishment of a reverse genetics system for this virus has enabled the development of genetically modified recombinant NDV viruses with improved oncolytic and immunotherapeutic properties. In this chapter, we describe the materials and methods involved in the in vitro cloning and rescue of NDV expressing murine 4-1BBL as well as the in vivo evaluation of NDV expressing 4-1BBL in a B16-F10 murine melanoma model.

Entities:  

Keywords:  Immunotherapy; Newcastle disease virus; Oncolytic vector; Reverse genetics; Virus rescue

Year:  2020        PMID： 31486036      PMCID： PMC7370866          DOI： 10.1007/978-1-4939-9794-7_9

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN： 1064-3745


  41 in total

1.  A ten-year follow-up on stage II malignant melanoma patients treated postsurgically with Newcastle disease virus oncolysate.

Authors:  W A Cassel; D R Murray
Journal:  Med Oncol Tumor Pharmacother       Date:  1992

2.  B16 as a mouse model for human melanoma.

Authors:  W W Overwijk; N P Restifo
Journal:  Curr Protoc Immunol       Date:  2001-05

3.  Contribution of antiviral immunity to oncolysis by Newcastle disease virus in a murine lymphoma.

Authors:  M D Eaton; J D Levinthal; A R Scala
Journal:  J Natl Cancer Inst       Date:  1967-12       Impact factor: 13.506

4.  Recombinant newcastle disease virus expressing a foreign viral antigen is attenuated and highly immunogenic in primates.

Authors:  Alexander Bukreyev; Zhuhui Huang; Lijuan Yang; Subbiah Elankumaran; Marisa St Claire; Brian R Murphy; Siba K Samal; Peter L Collins
Journal:  J Virol       Date:  2005-11       Impact factor: 5.103

5.  Mapping of the RNA promoter of Newcastle disease virus.

Authors:  Fernando Marcos; Laura Ferreira; Jerome Cros; Man-Seong Park; Takaaki Nakaya; Adolfo García-Sastre; Enrique Villar
Journal:  Virology       Date:  2005-01-20       Impact factor: 3.616

6.  Adjuvant treatment of locally advanced renal cancer with autologous virus-modified tumor vaccines.

Authors:  H H Kirchner; P Anton; J Atzpodien
Journal:  World J Urol       Date:  1995       Impact factor: 4.226

7.  Attenuated veterinary virus vaccine for the treatment of cancer.

Authors:  L K Csatary; S Eckhardt; I Bukosza; F Czegledi; C Fenyvesi; P Gergely; B Bodey; C M Csatary
Journal:  Cancer Detect Prev       Date:  1993

8.  Studies on the biological characteristics of the Newcastle disease virus (NDV) adapted to the brain of newborne mice.

Authors:  J SINKOVICS
Journal:  Arch Gesamte Virusforsch       Date:  1957

Review 9.  Overview of phase I studies of intravenous administration of PV701, an oncolytic virus.

Authors:  Robert M Lorence; Andrew L Pecora; Pierre P Major; Sebastien J Hotte; Scott A Laurie; M Scot Roberts; William S Groene; Michael K Bamat
Journal:  Curr Opin Mol Ther       Date:  2003-12

10.  Efficient and Robust Paramyxoviridae Reverse Genetics Systems.

Authors:  Shannon M Beaty; Arnold Park; Sohui T Won; Patrick Hong; Michael Lyons; Frederic Vigant; Alexander N Freiberg; Benjamin R tenOever; W Paul Duprex; Benhur Lee
Journal:  mSphere       Date:  2017-03-29       Impact factor: 4.389
View more
  6 in total

1.  Engineering Newcastle Disease Virus as an Oncolytic Vector for Intratumoral Delivery of Immune Checkpoint Inhibitors and Immunocytokines.

Authors:  Gayathri Vijayakumar; Stephen McCroskery; Peter Palese
Journal:  J Virol       Date:  2020-01-17       Impact factor: 5.103

Review 2.  Development and Scalable Production of Newcastle Disease Virus-Vectored Vaccines for Human and Veterinary Use.

Authors:  Julia P C Fulber; Amine A Kamen
Journal:  Viruses       Date:  2022-05-06       Impact factor: 5.818

3.  Oncolytic Newcastle disease virus expressing a checkpoint inhibitor as a radioenhancing agent for murine melanoma.

Authors:  Gayathri Vijayakumar; Peter Palese; Peter H Goff
Journal:  EBioMedicine       Date:  2019-10-29       Impact factor: 8.143

4.  Newcastle disease virus (NDV) expressing the spike protein of SARS-CoV-2 as a live virus vaccine candidate.

Authors:  Weina Sun; Sarah R Leist; Stephen McCroskery; Yonghong Liu; Stefan Slamanig; Justine Oliva; Fatima Amanat; Alexandra Schäfer; Kenneth H Dinnon; Adolfo García-Sastre; Florian Krammer; Ralph S Baric; Peter Palese
Journal:  EBioMedicine       Date:  2020-11-21       Impact factor: 8.143

5.  A Newcastle Disease Virus (NDV) Expressing a Membrane-Anchored Spike as a Cost-Effective Inactivated SARS-CoV-2 Vaccine.

Authors:  Weina Sun; Stephen McCroskery; Wen-Chun Liu; Sarah R Leist; Yonghong Liu; Randy A Albrecht; Stefan Slamanig; Justine Oliva; Fatima Amanat; Alexandra Schäfer; Kenneth H Dinnon; Bruce L Innis; Adolfo García-Sastre; Florian Krammer; Ralph S Baric; Peter Palese
Journal:  Vaccines (Basel)       Date:  2020-12-17

Review 6.  Transboundary Animal Diseases, an Overview of 17 Diseases with Potential for Global Spread and Serious Consequences.

Authors:  Elizabeth A Clemmons; Kendra J Alfson; John W Dutton
Journal:  Animals (Basel)       Date:  2021-07-08       Impact factor: 2.752
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.